Literature DB >> 8076344

ERG gene is translocated in an Ewing's sarcoma cell line.

T Dunn1, L Praissman, N Hagag, M V Viola.   

Abstract

Ewing's sarcoma (ES) and related neoplasias are characterized by the reciprocal translocation, t(11;22)(q24;q12). The translocation has been reported to generate a fusion gene between the EWS (a previously undescribed gene on chromosome 22) and FLI1 genes. We report a similar translocation of EWS and FLI1 in an Askin's tumor cell line (SK-NM-C). Further, we describe an alternative translocation in an ES cell line (#5838) in which the 5' end of the EWS gene is juxtaposed to the 3' end of the ERG gene. The ERG gene is on chromosome 21, but no microscopically visible changes in chromosome 21 were observed. Elevated steady state levels of the EWS/ERG fusion gene transcript were detected in the #5838 cell line. This is the first report of a structural alteration of ERG in human cancer. Also, it confirms a general mechanism of generating putative oncogenic fusion genes by placing an ETS DNA binding domain in direct proximity to the carboxy terminus domain (CTD) related region of the EWS gene.

Entities:  

Mesh:

Year:  1994        PMID: 8076344     DOI: 10.1016/0165-4608(94)90063-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  14 in total

1.  Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides.

Authors:  J A Toretsky; Y Connell; L Neckers; N K Bhat
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.

Authors:  S Scheidler; W J Fredericks; F J Rauscher; F G Barr; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

3.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

4.  Molecular diagnosis in Ewing family tumors: the Rizzoli experience--222 consecutive cases in four years.

Authors:  Gabriella Gamberi; Stefania Cocchi; Stefania Benini; Giovanna Magagnoli; Luca Morandi; Jennifer Kreshak; Marco Gambarotti; Piero Picci; Licciana Zanella; Marco Alberghini
Journal:  J Mol Diagn       Date:  2011-03-31       Impact factor: 5.568

5.  Targeting PI3K in neuroblastoma.

Authors:  Volker Spitzenberg; Christian König; Susanne Ulm; Romina Marone; Luise Röpke; Jörg P Müller; Michael Grün; Reinhard Bauer; Ignacio Rubio; Matthias Paul Wymann; Astrid Voigt; Reinhard Wetzker
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-12       Impact factor: 4.553

6.  Saccharomyces cerevisiae as a model system to define the chromosomal instability phenotype.

Authors:  Christopher D Putnam; Vincent Pennaneach; Richard D Kolodner
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

Review 7.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Differential detection of alternatively spliced variants of Ciz1 in normal and cancer cells using a custom exon-junction microarray.

Authors:  Faisal A Rahman; Naveed Aziz; Dawn Coverley
Journal:  BMC Cancer       Date:  2010-09-10       Impact factor: 4.430

9.  Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO.

Authors:  Jennifer L Alabran; Adam Cheuk; Karen Liby; Michael Sporn; Javed Khan; John Letterio; Konstantin S Leskov
Journal:  Cancer Biol Ther       Date:  2008-05-07       Impact factor: 4.742

10.  CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.

Authors:  Sina Gogolin; Volker Ehemann; Gabriele Becker; Lena M Brueckner; Daniel Dreidax; Steffen Bannert; Ingo Nolte; Larissa Savelyeva; Emma Bell; Frank Westermann
Journal:  Cell Cycle       Date:  2013-03-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.